Skip to content
10-Q

Quarterly Report

OptimizeRx Corp OPRX

0001448431-26-000011

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 29, 2026 18.77M sh
Shares Diluted Q1 2026 · Mar 31, 2026 18.76M sh
Shares Diluted Q1 2026 · Mar 31, 2025 18.47M sh
Capex Q1 2026 · Mar 31, 2026 $21K
Capex Q1 2026 · Mar 31, 2025 $27K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$467K
Operating Cash Flow Q1 2026 · Mar 31, 2025 $3.86M
Long Term Debt Q1 2026 · Mar 31, 2026 $21.34M
Long Term Debt Q1 2026 · Dec 31, 2025 $21.42M
Short Term Debt Q1 2026 · Mar 31, 2026 $2M
Short Term Debt Q1 2026 · Dec 31, 2025 $4.26M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $20.17M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $23.37M
Stockholders Equity Q1 2026 · Mar 31, 2026 $129.61M
Stockholders Equity Q1 2026 · Dec 31, 2025 $128.29M
Stockholders Equity Q1 2026 · Mar 31, 2025 $116.27M
Stockholders Equity Q1 2026 · Dec 31, 2024 $117M
Current Liabilities Q1 2026 · Mar 31, 2026 $10.46M
Current Liabilities Q1 2026 · Dec 31, 2025 $21.26M
Total Liabilities Q1 2026 · Mar 31, 2026 $37.65M
Total Liabilities Q1 2026 · Dec 31, 2025 $48.62M
Current Assets Q1 2026 · Mar 31, 2026 $56.17M
Current Assets Q1 2026 · Dec 31, 2025 $64.72M
Total Assets Q1 2026 · Mar 31, 2026 $167.26M
Total Assets Q1 2026 · Dec 31, 2025 $176.92M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.03
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.12
Eps Basic Q1 2026 · Mar 31, 2026 −$0.03
Eps Basic Q1 2026 · Mar 31, 2025 −$0.12
Rd Expense Q1 2026 · Mar 31, 2026 $3.4M
Rd Expense Q1 2026 · Mar 31, 2025 $3.25M
Net Income Q1 2026 · Mar 31, 2026 −$495K
Net Income Q1 2026 · Mar 31, 2025 −$2.2M
Operating Income Q1 2026 · Mar 31, 2026 $396K
Operating Income restated Q1 2026 · Mar 31, 2025 −$2.1M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $4.91M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $8.58M